Have “Candid Conversations” on Urothelial Cancer with Andrea Necchi, Matt Galsky, Shilpa Gupta & Michiel van der Heijden for strategies to personalize care plans with innovative #BladderCancer tx. At #ASCO24 or online 5/31 at 6:30 PM CDT. Produced with PeerView: bit.ly/2024BladderT

Honored to have been at this event. thank you dear Dame Sally and Prince William for making the time to endorse efforts combatting AMR & for making the time to meet with us, and hear more about our independent Access to Medicine Foundation in guiding progress made by the #pharna industry to ensure

Does oncologic treatment for very advanced disease improve survival? 1⃣The study analyzed 78,446 adult patients with six common metastatic solid tumors. It found no significant survival benefit for patients receiving more systemic therapy for very advanced cancer. 2⃣There was no

We collaborated with PeerView for Real Talk on Urothelial Cancer! Join Andrea Necchi, Matt Galsky, Shilpa Gupta & Michiel van der Heijden on 5/31 at 6:30 PM CDT during #ASCO24 in person or online for a #BladderCancer #MedEd event: bit.ly/2024BladderT #Oncology #Urology #MedTwitter

The #ASCO24 highlight IMO. Currently 3 peri-operative IO approaches: adjuvant, neoadjuvant or both. NADINE tests neoadjuvant vs adjuvant. If +ve and neoadjuvant IO >adjuvant then shorter stronger peri-operative IO maybe better than longer adjuvant/combined approaches(+/- ctDNA)

CQO (Chief Question Officer) has been spotted, the GU section of #ASCO24 has truly begun! Petros Grivas Toni Choueiri, MD Tom Powles Ignacio Duran Uromigos Enrique Grande Laura S. Mertens Matt Galsky

Important data by Matt Galsky et al. CM901 trial confirming better outcomes with LN-only mets in mUC (favorable prognostic factor across therapies). Impressive ORR, PFS, OS, DoCR in this subset. Similar concept in EV302 by Michiel van der Heijden #GU24 #ASCO24 OncoAlert ASCO Guru P. Sonpavde, MD

What a week it has been for #neoadjuvant #immunotherapy The Netherlands Cancer Institute . Discussing, working together and having fun with some of the greatest minds in the field across tumor types is an honor and a privilege! MarleenKokLab Christian Blank John Haanen Michiel van der Heijden #tinacascone

The European Commission has approved nivolumab paired with cisplatin and gemcitabine for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma. Michiel van der Heijden The Netherlands Cancer Institute #oncology #blcsm onclive.com/view/frontline…

Positive results from the NIAGARA Phase III trial showed durvalumab with neoadjuvant chemo then cystectomy had a statistically significant and clinically meaningful improvement in EFS & OS versus chemo/cystectomy alone in muscle invasive bladder cancer astrazeneca.com/media-centre/p…

Final team from @uromigos cup 🏆🏆🏆for #nashvillelive. Dutch 🇳🇱 🇳🇱 🇳🇱 team of Axel Bex, Christian Blank, Laura Mertens and Micheil Van der Heijden answer a range of relevant and sometimes irrelevant questions to get to Nashville podcasters.spotify.com/pod/show/the-u…

1/1 Today ✍️ Journal of Clinical Oncology Sometimes treating TNBC can be challenging. Nowadays, academic clin res to improve treatm for TNBC can also be challenging. How do we get from one-size fits all with 4 types of chemo plus 1yr of pembro to a personalized treatm? ascopubs.org/doi/10.1200/JC…

Platinum-based chemotherapy affects immune cell composition and tumor microenvironment in urothelial cancer. Increases in CD8+ T cells and PD-L1+ cells, but also fibroblast-based TGF-β signaling, may explain mixed results in clinical trials with chemo and immune checkpoint

Results of chemo+IO have produced inconsistent results in urothelial cancer. Opposing effects of pro- and anti-inflammatory changes may explain some of this. Uromigos Laura S. Mertens MarleenKokLab Myriam Chalabi Petros Grivas Matt Galsky The Netherlands Cancer Institute Tom Powles aacrjournals.org/clincancerres/…

Research from leila akkari's research group shows that white blood cells loaded with cholesterol play a critical role in the growth of #glioblastoma. These fat-laden macrophages influence the local immune response and help the tumor survive. Read more ➡️ bit.ly/3SNqMwZ

Looking forward to a fantastic ESMO - Eur. Oncology #esmo24 with fantastic speakers, excellent content, collaboration, exchange, mentorship & networking! Andres Cervantes George Pentheroudakis silke gillessen Tom Powles Toni Choueiri, MD FabriceAndre Matteo Lambertini, MD PhD Laurence Albiges ylt Shilpa Gupta OncoAlert

The EMA has approved Enfortumab Vedotin and pembrolizumab for 1st line urothelial cancer. It supersedes 1st platinum based therapy as the new standard of care in Europe. astellas.com/en/news/29371?…